News Room

Optherion’s Genetic Research in Dry AMD Featured in Forbes

Article Says “Breakthrough” May Offer Hope for Millions.

Optherion, Inc. Completes $37 Million Start Up Financing

Financing will advance development of diagnostics and disease-modifying therapeutics for dry and wet age-related macular degeneration and other diseases associated with alternative complement system.

Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations

Optherion, Inc. announced today that it has licensed from the University of Pittsburgh the worldwide rights to develop diagnostic products for AMD associated with specific variations in genes on Chromosome 10.